Skip to content
Font Size

Treatment Option Overview for Prostate Cancer

    Table 9. Treatment Options by Stage for Prostate Cancer continued...

    Hormonal Therapy and Its Complications

    Several different hormonal approaches are used in the management of various stages of prostate cancer.

    These approaches include the following:

    Bilateral orchiectomy

    Benefits of bilateral orchiectomy include the following:[34]

    • Ease of the procedure.
    • Compliance.
    • Immediacy in lowering testosterone levels.
    • Low cost relative to the other forms of androgen deprivation therapy.

    Disadvantages of bilateral orchiectomy include the following:[34,73]

    Bilateral orchiectomy has also been associated with an elevated risk of coronary heart disease and myocardial infarction.[74,75,76]

    (Refer to the PDQ summary on Sexuality and Reproductive Issues for more information on loss of libido and impotence; refer to the PDQ summary on Fever, Sweats, and Hot Flashes.)

    Estrogen therapy

    Estrogens at a dose of 3 mg per day of diethylstilbestrol (DES) will achieve castrate levels of testosterone. Like orchiectomy, estrogens may cause loss of libido and impotence. Estrogens also cause gynecomastia, and prophylactic low-dose radiation therapy to the breasts is given to prevent this complication.

    DES is no longer manufactured or marketed in the United States and is seldom used today because of the risk of serious side effects, including myocardial infarction, cerebrovascular accidents, and pulmonary embolism.

    Luteinizing hormone-releasing hormone (LH-RH) agonist therapy

    LH-RH agonists, such as leuprolide, goserelin, and buserelin lower testosterone to castrate levels. Like orchiectomy and estrogens, LH-RH agonists cause impotence, hot flashes, and loss of libido. Tumor flare reactions may occur transiently but can be prevented by antiandrogens or short-term estrogens at a low dose for several weeks.

    There is some evidence that LH-RH agonists are associated with increased risk of cardiovascular morbidity or mortality, although the results are conflicting.[74,75,76,77]

    Evidence (LH-RH agonists and cardiovascular disease):

    1. In a population-based study within the Department of Veterans Affairs' system, LH-RH agonists were associated with an increased risk of diabetes as well as cardiovascular disease, including coronary heart disease, myocardial infarction, sudden death, and stroke.[74,75,76]
    2. A systematic evidence review and meta-analysis of eight trials (4,141 patients) of men with nonmetastatic prostate cancer who were randomly assigned to receive or not receive LH-RH agonists found no difference in cardiovascular death rates (11.0% vs. 11.2%; RRdeath of 0.93; 95% CI, 0.79–1.10; P = .41).[78] Median follow-up in those studies was 7.6 to 13.2 years. No excess risk of LH-RH agonists was found regardless of treatment duration or patient age (median age of <70 or ≥70 years).
    1|2|3|4|5|6|7|8|9|10|11|12|13

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
     
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
     
    cancer fighting foods
    SLIDESHOW
    15 Cancer Symptoms Men Ignore
    FEATURE
     
    Prostate Enlarged
    VIDEO
    Picture Of The Prostate
    ANATOMY
     
    Prostate Cancer Quiz
    QUIZ
    screening tests for men
    SLIDESHOW
     
    Prostate Cancer Symptoms
    VIDEO
    Vitamin D
    SLIDESHOW